PubMed ID:
34644706
Public Release Type:
Journal
Publication Year: 2021
Affiliation: Renal Research Institute, New York, New York, USA.; University Health Network Toronto, Toronto, Ontario, Canada.; University of Illinois College of Medicine, Chicago, Illinois, USA.; University of California Davis, Davis, California, USA.; University of Utah, Salt Lake City, Utah, USA.; University of California Davis, Davis, California, USA.; Yale New Haven Health System, New Haven, Connecticut, USA.; Renal Research Institute, New York, New York, USA.; Cleveland Clinic Foundation, Cleveland, Ohio, USA.; Cleveland Clinic Foundation, Cleveland, Ohio, USA.; Western University, London, Ontario, Canada.; Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.; Stanford University School of Medicine, Stanford, California, USA.; Renal Research Institute, New York, New York, USA.
DOI:
https://doi.org/10.1159/000519339
Authors:
Raimann Jochen G, Chan Christopher T, Daugirdas John T, Depner Thomas, Greene Tom, Kaysen George A, Kliger Alan S, Kotanko Peter, Larive Brett, Beck Gerald, Lindsay Robert McGregor, Rocco Michael V, Chertow Glenn M, Levin Nathan W
Request IDs:
20991
,
21295
Studies:
Frequent Hemodialysis Network: Nocturnal Study
The Frequent Hemodialysis Network (FHN) Daily and Nocturnal trials aimed to compare the effects of hemodialysis (HD) given 6 versus 3 times per week. More frequent in-center HD significantly reduced left-ventricular mass (LVM), with more pronounced effects in patients with low urine volumes. In this study, we aimed to explore another potential effect modifier: the predialysis serum sodium (SNa) and related proxies of plasma tonicity.